LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 298

Search options

  1. Article: Treatment of small airway diseases

    Buhl, Roland

    today and tomorrow

    (Pneumologie ; 63, Suppl. 2)

    2009  

    Author's details Gasthrsg. R. Buhl
    Series title Pneumologie ; 63, Suppl. 2
    Collection
    Language German ; English
    Size S. S95 - S116 : Ill., graph. Darst.
    Publisher Thieme
    Publishing place Stuttgart
    Publishing country Germany
    Document type Article
    HBZ-ID HT016189554
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Uh II Zs 142 -63,Suppl.2- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: As-needed ICS/formoterol or as-needed SABA in mild asthma?

    Krishnan, Jerry A / Buhl, Roland

    The European respiratory journal

    2024  Volume 63, Issue 4

    MeSH term(s) Humans ; Formoterol Fumarate/therapeutic use ; Asthma/drug therapy ; Budesonide
    Chemical Substances Formoterol Fumarate (W34SHF8J2K) ; Budesonide (51333-22-3)
    Language English
    Publishing date 2024-04-04
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 639359-7
    ISSN 1399-3003 ; 0903-1936
    ISSN (online) 1399-3003
    ISSN 0903-1936
    DOI 10.1183/13993003.02308-2023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2322: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 292: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Die neue fachärztliche Asthma-Leitlinie 2023: Wegbegleiter und Meilenstein in der Asthma-Versorgung.

    Lommatzsch, Marek / Buhl, Roland

    Pneumologie (Stuttgart, Germany)

    2023  Volume 77, Issue 8, Page(s) 459–460

    Title translation The new asthma guidelines for respiratory specialists 2023: companion and milestone in asthma care.
    Language German
    Publishing date 2023-08-24
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 607630-0
    ISSN 1438-8790 ; 0934-8387
    ISSN (online) 1438-8790
    ISSN 0934-8387
    DOI 10.1055/a-2122-8941
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh II Zs.142: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 54: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Die neue fachärztliche Asthma-Leitlinie 2023: Wegbegleiter und Meilenstein in der Asthma-Versorgung

    Lommatzsch, Marek / Buhl, Roland

    Pneumologie

    2023  Volume 77, Issue 08, Page(s) 459–460

    Language German
    Publishing date 2023-08-01
    Publisher Georg Thieme Verlag KG
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 607630-0
    ISSN 1438-8790 ; 0934-8387
    ISSN (online) 1438-8790
    ISSN 0934-8387
    DOI 10.1055/a-2122-8941
    Database Thieme publisher's database

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh II Zs.142: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 54: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Schweres und schwer zu behandelndes Asthma bronchiale - Definition, Diagnose und Update der Therapieoptionen

    Buhl, Roland

    Arzt & Praxis

    2018  Volume 72, Issue 8, Page(s) 29

    Language German
    Document type Article
    ZDB-ID 1224197-0
    ISSN 0048-5128
    Database Current Contents Medicine

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 868: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Reply to the Letter Entitled "FeNO Variability when Using Different Analyzers at the Joint ATS/ERS Guideline Cutoff".

    Korn, Stephanie / Buhl, Roland

    Respiration; international review of thoracic diseases

    2019  Volume 99, Issue 1, Page(s) 94

    MeSH term(s) Breath Tests ; Exhalation ; Nitric Oxide
    Chemical Substances Nitric Oxide (31C4KY9ESH)
    Language English
    Publishing date 2019-12-11
    Publishing country Switzerland
    Document type Letter ; Comment
    ZDB-ID 206674-9
    ISSN 1423-0356 ; 0025-7931
    ISSN (online) 1423-0356
    ISSN 0025-7931
    DOI 10.1159/000504631
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh II Zs.138: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Future perspectives of anticholinergics for the treatment of asthma in adults and children.

    Buhl, Roland / Hamelmann, Eckard

    Therapeutics and clinical risk management

    2019  Volume 15, Page(s) 473–485

    Abstract: Despite major advances in therapeutic interventions and the availability of detailed treatment guidelines, a high proportion of patients with symptomatic asthma remain uncontrolled. Asthma management is largely guided by the Global Initiative for Asthma ( ...

    Abstract Despite major advances in therapeutic interventions and the availability of detailed treatment guidelines, a high proportion of patients with symptomatic asthma remain uncontrolled. Asthma management is largely guided by the Global Initiative for Asthma (GINA) strategy and is based on a backbone of inhaled corticosteroid (ICS) therapy with the use of additional therapies to achieve disease control. Inhaled long-acting bronchodilators alone and in combination are the preferred add-on treatment options. Although long-acting muscarinic antagonists (LAMAs) are a relatively recent addition to disease management recommendations for asthma, tiotropium has been extensively studied in a large clinical trial program. In Europe and the United States, tiotropium is approved for patients aged ≥6 years and uncontrolled on medium- to high-dose ICS/long-acting β
    Language English
    Publishing date 2019-03-14
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2186560-7
    ISSN 1178-203X ; 1176-6336
    ISSN (online) 1178-203X
    ISSN 1176-6336
    DOI 10.2147/TCRM.S180890
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6067: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Thoracic skeletal muscle mass predicts mortality in patients with surgery for pleural empyema: A case control study.

    Galata, Christian / Schiller, Philipp / Müller, Lukas / Karampinis, Ioannis / Stamenovic, Davor / Buhl, Roland / Kreuter, Michael / Roessner, Eric Dominic

    Thoracic cancer

    2024  

    Abstract: Background: This study investigated the role of the thoracic skeletal muscle mass as a marker of sarcopenia on postoperative mortality in pleural empyema.: Methods: All consecutive patients (n = 103) undergoing surgery for pleural empyema in a single ...

    Abstract Background: This study investigated the role of the thoracic skeletal muscle mass as a marker of sarcopenia on postoperative mortality in pleural empyema.
    Methods: All consecutive patients (n = 103) undergoing surgery for pleural empyema in a single tertiary referral center between January 2020 and December 2022 were eligible for this study. Thoracic skeletal muscle mass index (TSMI) was determined from preoperative computed tomography scans. The impact of TSMI and other potential risk factors on postoperative in-hospital mortality was retrospectively analyzed.
    Results: A total of 97 patients were included in this study. The in-hospital mortality rate was 13.4%. In univariable analysis, low values for preoperative TSMI (p = 0.020), low preoperative levels of thrombocytes (p = 0.027) and total serum protein (p = 0.046) and higher preoperative American Society of Anesthesiologists (ASA) category (p = 0.007) were statistically significant risk factors for mortality. In multivariable analysis, only TSMI (p = 0.038, OR 0.933, 95% CI: 0.875-0.996) and low thrombocytes (p = 0.031, OR 0.944, 95% CI: 0.988-0.999) remained independent prognostic factors for mortality.
    Conclusions: TSMI was a significant prognostic risk factor for postoperative mortality in patients with pleural empyema. TSMI may be suitable for risk stratification in this disease with high morbidity and mortality, which may have further implications for the selection of the best treatment strategy.
    Language English
    Publishing date 2024-04-10
    Publishing country Singapore
    Document type Journal Article
    ZDB-ID 2625856-0
    ISSN 1759-7714 ; 1759-7706
    ISSN (online) 1759-7714
    ISSN 1759-7706
    DOI 10.1111/1759-7714.15307
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6921: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: The Treatment of Mild and Moderate Asthma in Adults.

    Lommatzsch, Marek / Buhl, Roland / Korn, Stephanie

    Deutsches Arzteblatt international

    2020  Volume 117, Issue 25, Page(s) 434–444

    Abstract: Background: Asthma is a chronic inflammatory airway disease that usually causes variable airway obstruction. It affects 5-10% of the German population.: Methods: This review is based on relevant publications retrieved by a selective search, as well ... ...

    Abstract Background: Asthma is a chronic inflammatory airway disease that usually causes variable airway obstruction. It affects 5-10% of the German population.
    Methods: This review is based on relevant publications retrieved by a selective search, as well as on national and international guidelines on the treatment of mild and moderate asthma in adults.
    Results: The goal of treatment is to attain optimal asthma control with a minimal risk of exacerbations and mortality, loss of pulmonary function, and drug side effects. This can be achieved with a combination of pharmacotherapy and non-drug treatment including patient education, exercise, smoking cessation, and rehabilitation. Pharmacohterapy is based on inhaled corticosteroids (ICS) and bronchodilators. It is recommended that mild asthma should be treated only when needed, either with a fixed combination of ICS and formoterol or with short-acting bronchodilators. For moderate asthma, maintenance treatment is recommended, with an inhaled fixed combinations of ICS and long-acting beta-mimetics, possibly supplemented with longacting anticholinergic agents. Allergen immunotherapy, i.e., desensitization treatment, should be considered if the allergic component of asthma is well documented and the patient is not suffering from uncontrolled asthma. Asthma control should be monitored at regular intervals, and the treatment should be adapted accordingly.
    Conclusion: The treatment of asthma in adults should be individually tailored, with anti-inflammatory treatment as its main component.
    MeSH term(s) Administration, Inhalation ; Adrenal Cortex Hormones ; Adult ; Anti-Asthmatic Agents/therapeutic use ; Asthma/drug therapy ; Drug Therapy, Combination ; Formoterol Fumarate ; Humans
    Chemical Substances Adrenal Cortex Hormones ; Anti-Asthmatic Agents ; Formoterol Fumarate (W34SHF8J2K)
    Language English
    Publishing date 2020-09-03
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 2406159-1
    ISSN 1866-0452 ; 1866-0452
    ISSN (online) 1866-0452
    ISSN 1866-0452
    DOI 10.3238/arztebl.2020.0434
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD 'real world' study.

    Vogelmeier, Claus F / Worth, Heinrich / Buhl, Roland / Criée, Carl-Peter / Gückel, Eva / Kardos, Peter

    Respiratory research

    2022  Volume 23, Issue 1, Page(s) 109

    Abstract: Introduction: Chronic obstructive pulmonary disease (COPD) guidelines recommend reserving triple therapy of inhaled corticosteroid (ICS), long-acting β: Methods: DACCORD was a longitudinal, non-interventional 'real-world' study in three cohorts. This ...

    Abstract Introduction: Chronic obstructive pulmonary disease (COPD) guidelines recommend reserving triple therapy of inhaled corticosteroid (ICS), long-acting β
    Methods: DACCORD was a longitudinal, non-interventional 'real-world' study in three cohorts. This manuscript describes the results of Cohort 3, which recruited patients with COPD who had received triple therapy for ≥ 6 months. Prior to entry, each patient's physician decided to continue triple therapy, or switch to a LABA/LAMA; patients were then followed for 12 months, with exacerbations and COPD Assessment Test (CAT) data recorded every 3 months. The primary endpoint was the time until COPD worsening, defined as the occurrence of a moderate/severe exacerbation or clinically relevant CAT worsening.
    Results: Of the 1192 patients recruited into the study, 967 completed the end-of-study visit and ≥ 2 of the three interim visits, 292 and 675 receiving LABA/LAMA and triple therapy, respectively. Most baseline demographics were similar between the two groups. A lower proportion of patients in the LABA/LAMA group had COPD worsening than with triple therapy (32.5% vs 55.7% at 12 months), with the time to worsening extended in the LABA/LAMA group (hazard ratio 2.004, p < 0.001). In addition, a significantly lower proportion of patients in the LABA/LAMA group exacerbated (18.5% vs 28.7%; p < 0.001), accompanied by a greater improvement from baseline in CAT total score. Overall, fewer patients in the LABA/LAMA group reported adverse events than in the triple therapy group (12.9% vs 15.1%).
    Conclusions: These results suggest that in a real world setting physicians are able to identify patients who can be 'stepped down' from triple therapy to LABA/LAMA. Following step down, there was no overall decline in COPD-indeed, some patients had better outcomes.
    MeSH term(s) Administration, Inhalation ; Adrenal Cortex Hormones/adverse effects ; Adrenergic beta-2 Receptor Agonists/adverse effects ; Drug Therapy, Combination ; Humans ; Muscarinic Antagonists/adverse effects ; Pulmonary Disease, Chronic Obstructive/complications ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/drug therapy
    Chemical Substances Adrenal Cortex Hormones ; Adrenergic beta-2 Receptor Agonists ; Muscarinic Antagonists
    Language English
    Publishing date 2022-05-02
    Publishing country England
    Document type Journal Article
    ZDB-ID 2041675-1
    ISSN 1465-993X ; 1465-993X
    ISSN (online) 1465-993X
    ISSN 1465-993X
    DOI 10.1186/s12931-022-02037-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top